A Phase 1/2 interventional study of T3D-959 in Alzheimer's Disease, sponsored by T3D Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by T3D Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,094th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 67 in phase 1/2, and was the 726th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 72 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
T3D Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
T3D Therapeutics, Inc. has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959. Subjects will be evaluated for changes from baseline in cerebral metabolic rate of glucose (FDG-PET imaging), functional connectivity of the hippocampus (BOLD-fMRI), and cognitive function (ADAS-Cog11 and DSST) as well as assessed for safety and tolerability to T3D-959.
An expanded access extension is planed to provide access to study medication to subjects who have completed the main study and requested continued use.
T3D-959 is an orally-delivered, once-a-day administered, small molecule dual nuclear receptor agonist that has been shown in animal and Phase 1 studies in normal human subjects to be safe and well tolerated. The purpose of this clinical study in AD patients is to demonstrate mechanistic proof of concept that T3D-959, can produce desired changes in cerebral glucose metabolism and functional connectivity that may indicate potential for cognitive improvement. The therapeutic approach to be tested is based on two suppositions; (A) ameliorating multiple pathologies in the disease with a single therapy may provide a superior clinical benefit than therapeutic approaches which target a single pathology and (B) correcting insulin resistance in the brain, (highly correlated with AD and potential key driver of AD pathophysiology) and peripherally may be disease remedial.
The brain requires integral insulin signaling for metabolic homeostasis and neuronal plasticity. Insulin resistance disrupts energy balance and signaling networks needed for a broad range of functions. Impaired insulin signaling in neurons enhances apoptosis, promotes oxidative cell death induced by Abeta1-42, increases secretion of Abeta1-42, blocks removal of extracellular Abeta oligomers and increases plaque loads. A growing body of evidence suggests that brain insulin resistance promotes or possibly is the trigger of key pathologies in AD and is supported by observed changes in levels of insulin signaling molecules in AD forebrains and associated changes in memory. Pre-clinical studies in animals have demonstrated the insulin sensitizing activity of T3D-959 and ability to improve multiple pathologies of AD in a rat model of disease.
This non-placebo controlled trial will be conducted in one to three clinical centers. Thirty six (36) patients with mild-to-moderate Alzheimer's disease will be randomly assigned to once daily, orally administered treatment with 3mg, 10mg, 30mg or 90mg doses of T3D-959. Participants will be treated for two weeks and will undergo at baseline and at two weeks; FDG-PET scans to measure brain glucose metabolism, BOLD fMRI scans to measure functional connectivity of the hippocampus, venous blood draws for biomarker analysis and ApoE genotyping, and ADAS-Cog11 and DSST cognitive testing. For monitoring potential toxicities of the drug subjects will undergo physical examination, neurological examination, adverse event review, blood chemistries, and pharmacokinetic (PK) analyses for T3D-959 plasma levels.
BOLD fMRI definition of terms:
GoF (Goodness of Fit): The degree to which the spatial extent and magnitude of one subject's default mode network (DMN) regions matches the one of an elderly control group.
Hippo-PreC Link (Hippocampus - Precuneus Link): The resting-state BOLD signal correlation strength between hippocampus and precuneus regions of interest.
GlobEff_DMN: (Global Efficiency from DMN Regions): The global efficiency among 11 pre-defined default mode network regions.
GlobEff_AAL: (Global Efficiency from AAL Regions): The global efficiency among 90 pre-defined cerebral regions based on automated anatomical labeling.
ALFF_lPCC_PreC: Amplitude of Low Frequency Fluctuations (ALFF) from left posterior cingulate cortex (PCC) and precuneus (PreC).
ALFF_rPCC_PreC: ALFF from right PCC and precuneus. fALFF_lPCC_PreC: Ratio ALFF from left PCC and precuneus. fALFF_rPCC_PreC: Ratio ALFF from right PCC and precuneus. ReHo_lPCC_PreC: Regional Homogeneity in left PCC and PreC. ReHo_rPCC_PreC: Regional Homogeneity in right PCC and PreC. ALFF_lIPL: ALFF from left inferior parietal lobule (IPL). ALFF_rIPL: ALFF from right IPL. fALFF_lIPL: Ratio ALFF from left IPL. fALFF_rIPL : Ratio ALFF from right IPL. ReHo_lIPL: Regional Homogeneity in left IPL. ReHo_rIPL: Regional Homogeneity in right IPL.
Expanded Access Extension: This is an open label 10 visit extension for up to 5 subjects who have completed the T3D959-201 protocol and whose caregivers and physician requested their continued treatment in an expanded access protocol. All subjects enrolled in this study will be treated with a 15mg q.d. dose of T3D959 for six months, regardless of their assigned dose level from the main study. A continued risk/benefit assessment by the investigator will be conducted at each visit to determine the need for treatment continuation. Subjects will be assessed for safety and tolerability to T3D-959 and evaluated for changes from baseline cognitive function via ADAS-Cog11 and DSST testing and global change via CIBIC-plus testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Expanded Access Extension :
Subjects must continue to meet the main study inclusion/exclusion criteria to insure continued safety to continue on a 6 months study extension
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
Drug: T3D-959
Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
Drug: T3D-959
Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
Drug: T3D-959
Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
Drug: T3D-959
The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region
Changes in relative brain glucose metabolism (delta R CMRgl) were measured by FDG-PET. At each time point, a ratio of the PET reading in a pre-defined region of interest (sROI), known to be affected by AD, and in a reference region (RR) that is spared in AD, is determined. This ratio is defined as "sROI index" (spared region). A second RR, brain white matter (WM), was also used in this calculation: sROI index" (WM) value. delta sROI is defined as change in the sROI index values, over the treatment period. In this study we are looking for changes in delta sROI with increasing doses of T3D-959. Dose dependent changes in delta sROI (AD spared) are compared to those observed with the WM as the RR: delta sROI (WM). Dose related changes in delta sROI suggests T3D-959 is entering the brain and effecting glucose metabolism in a dose dependent fashion.
Time frame: after 14 days of treatment
The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.
Changes in BOLD fMRI parameters such as GoF (see Study Description) over the course of two weeks of treatment, were obtained in this study. BOLD fMRI has been used in cross sectional and longitudinal studies of Alzheimer's subjects, for instance in the Alzheimer's Disease Neuroimaging Initiative studies. However, no studies monitoring Default Mode Networks measured parameters such as GoF, in the context of an effective AD therapeutic, as a result it is difficult to interpret the observed small changes listed in BOLD fMRI parameters obtained in this trial. Instead the changes in the listed BOLD fMRI parameters (EOT - BL) are reported without interpretation. These values represent changes in fMRI connectivity patterns over time and are unitless.
Time frame: after 14 days of treatment
Change From Baseline in the Score of the Digit Symbol Substitution Test
The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93.
Time frame: after 14 days of treatment
Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale
The 11-item Alzheimer's Disease Assessment Scale (ADAS-Cog 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. The score can range between 0 and 70. A higher score indicates more cognitive impairment. A positive change in the score indicates cognitive worsening. The minimum severity score is 0 and the maximum severity score is 70.
Time frame: after 14 days of treatment
Safety and Tolerability of Treatment With T3D-959 Over a 2-week Period in Subjects With Mild-to-moderate AD. New
Number of participants with treatment related adverse events (AEs) as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.
Time frame: after 14 days of treatment
| Milestone | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| Started | 9 | 9 | 10 | 8 |
| Completed | 8 | 9 | 9 | 8 |
| Not completed | 1 | 0 | 1 | 0 |
Changes in relative brain glucose metabolism (delta R CMRgl) were measured by FDG-PET. At each time point, a ratio of the PET reading in a pre-defined region of interest (sROI), known to be affected by AD, and in a reference region (RR) that is spared in AD, is determined. This ratio is defined as "sROI index" (spared region). A second RR, brain white matter (WM), was also used in this calculation: sROI index" (WM) value. delta sROI is defined as change in the sROI index values, over the treatment period. In this study we are looking for changes in delta sROI with increasing doses of T3D-959. Dose dependent changes in delta sROI (AD spared) are compared to those observed with the WM as the RR: delta sROI (WM). Dose related changes in delta sROI suggests T3D-959 is entering the brain and effecting glucose metabolism in a dose dependent fashion.
| ratio | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| delta sROI (AD spared) | 0.0015 ± 0.02057 | 0.0034 ± 0.01671 | -0.0204 ± 0.01952 | -0.0293 ± 0.01744 |
| delta sROI (white matter) | 0.0016 ± 0.04008 | 0.0053 ± 0.02471 | -0.0200 ± 0.01979 | -0.0355 ± 0.02303 |
Changes in BOLD fMRI parameters such as GoF (see Study Description) over the course of two weeks of treatment, were obtained in this study. BOLD fMRI has been used in cross sectional and longitudinal studies of Alzheimer's subjects, for instance in the Alzheimer's Disease Neuroimaging Initiative studies. However, no studies monitoring Default Mode Networks measured parameters such as GoF, in the context of an effective AD therapeutic, as a result it is difficult to interpret the observed small changes listed in BOLD fMRI parameters obtained in this trial. Instead the changes in the listed BOLD fMRI parameters (EOT - BL) are reported without interpretation. These values represent changes in fMRI connectivity patterns over time and are unitless.
| unitless | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| GoF (Goodness of Fit) | 0.0129 ± 0.08528 | -0.0120 ± 0.0646 | 0.0118 ± 0.03375 | 0.0076 ± 0.08755 |
| Hippo-PreC Link (Hippocampus - Precuneus Link) | -0.1213 ± 0.17904 | 0.1320 ± 0.22964 | 0.1196 ± 0.23035 | -0.0349 ± 0.18496 |
| GlobEff_DMN(Global Efficiency from DMN Regions) | 0.0033 ± 0.00734 | -0.0036 ± 0.00940 | -0.0004 ± 0.00926 | -0.0001 ± 0.00397 |
| GlobEff_AAL(Global Efficiency from AAL Regions) | -0.0001 ± 0.00664 | -0.0006 ± 0.00972 | -0.0031 ± 0.01060 | -0.0005 ± 0.00517 |
| ALFF_lPCC_PreC (Amplitude of Low Frequency Fluctua | -0.0578 ± 0.12314 | -0.0190 ± 0.11983 | -0.0505 ± 0.07463 | -0.0206 ± 0.10508 |
| ALFF_rPCC_PreC (ALFF from right PCC and precuneus) | -0.0752 ± 0.09059 | -0.0127 ± 0.12127 | -0.0097 ± 0.08362 | -0.0325 ± 0.11092 |
| fALFF_lPCC_PreC (Ratio ALFF from left PCC & prec | 0.0121 ± 0.03246 | 0.0068 ± 0.03510 | -0.0132 ± 0.03955 | -0.0167 ± 0.03284 |
| fALFF_rPCC_PreC (Ratio ALFF from right PCC & pre | -0.0080 ± 0.04094 | 0.0084 ± 0.04325 | -0.0007 ± 0.03913 | -0.0118 ± 0.04236 |
| ReHo_lPCC_PreC (Regional Homogeneity in left PCC a | -0.0665 ± 0.18502 | 0.0237 ± 0.14028 | -0.0369 ± 0.09702 | 0.0194 ± 0.20061 |
| ReHo_rPCC_PreC (Regional Homogeneity in right PCC | -0.0390 ± 0.06406 | -0.0663 ± 0.22082 | -0.0895 ± 0.10541 | -0.0041 ± 0.15836 |
| ALFF_lIPL (ALFF from left inferior parietal lobule | -0.0635 ± 0.09445 | 0.0104 ± 0.05763 | -0.0102 ± 0.12016 | -0.0401 ± 0.05657 |
| ALFF_rIPL(ALFF from right IPL) | -0.0493 ± 0.11288 | -0.0276 ± 0.12720 | 0.0346 ± 0.09654 | -0.1089 ± 0.13935 |
| fALFF_lIPL (Ratio ALFF from left IPL) | -0.0296 ± 0.03988 | 0.0164 ± 0.02269 | -0.0107 ± 0.06563 | -0.0350 ± 0.04570 |
| fALFF_rIPL (Ratio ALFF from right IPL) | -0.0342 ± 0.03912 | 0.0061 ± 0.03286 | 0.0023 ± 0.02771 | -0.0395 ± 0.05327 |
| ReHo_lIPL (Regional Homogeneity in left IPL) | -0.0694 ± 0.15420 | 0.0147 ± 0.14620 | -0.0249 ± 0.19178 | -0.0062 ± 0.06575 |
| ReHo_rIPL (Regional Homogeneity in right IPL) | -0.0694 ± 0.15420 | 0.0147 ± 0.14620 | -0.0249 ± 0.19178 | -0.0062 ± 0.06575 |
The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93.
| score on a scale | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| Change from baseline at end of treatment (day 14) | 4.429 ± 9.1626 | 1.000 ± 5.500 | 0.750 ± 3.6154 | 1.125 ± 4.5493 |
| Change from baseline at follow-up (day 21) | 5.375 ± 8.5011 | 3.111 ± 5.0111 | 4.000 ± 5.6789 | 6.625 ± 11.4385 |
The 11-item Alzheimer's Disease Assessment Scale (ADAS-Cog 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. The score can range between 0 and 70. A higher score indicates more cognitive impairment. A positive change in the score indicates cognitive worsening. The minimum severity score is 0 and the maximum severity score is 70.
| score on a scale | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| Change from baseline at end of treatment (day 14) | -2.367 ± 4.0417 | -0.552 ± 3.1467 | -2.709 ± 3.9801 | 1.970 ± 5.2191 |
| Change from baseline at follow-up (day 21) | -3.409 ± 3.5168 | -0.624 ± 3.8134 | -4.119 ± 3.8163 | 2.795 ± 4.1567 |
Number of participants with treatment related adverse events (AEs) as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.
| participants | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| Subjects with at Least One Serious Adverse Events | 0 | 0 | 0 | 0 |
| Subjects with at Least One Drug-related AE | 0 | 0 | 1 | 0 |
| Subjects with at Least One mild AE | 2 | 0 | 1 | 0 |
| Subjects with at Least One moderate AE | 1 | 0 | 2 | 0 |
| Subjects with at Least One serious AE | 0 | 0 | 0 | 0 |
Collected over pre treatment, during the two weeks of treatment and on follow-up one week after treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T3D-959 3mg | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| T3D-959 10mg | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| T3D-959 30mg | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| T3D-959 90mg | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg |
|---|---|---|---|---|
| TendonitisMusculoskeletal and connective tissue disorders | 1/9 | 0/9 | 0/10 | 0/8 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 0/9 | 0/9 | 1/10 | 0/8 |
| Age, Customized(Participants) | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg | Total |
|---|---|---|---|---|---|
| <=65 years | 2 | 2 | 3 | 1 | 8 |
| 65-74 years | 2 | 4 | 2 | 2 | 10 |
| 75-84 years | 3 | 3 | 1 | 5 | 12 |
| >84 years | 2 | 0 | 4 | 0 | 6 |
| Sex: Female, Male(Participants) | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg | Total |
|---|---|---|---|---|---|
| Female | 5 | 5 | 6 | 4 | 20 |
| Male | 4 | 4 | 4 | 4 | 16 |
| ApoE4 genotype(Participants) | T3D-959 3mg | T3D-959 10mg | T3D-959 30mg | T3D-959 90mg | Total |
|---|---|---|---|---|---|
| ApoE4 positive | 4 | 2 | 4 | 3 | 13 |
| ApoE4 negative | 4 | 7 | 5 | 5 | 21 |
Plan to share: Undecided
The record gives a start of Jul 2015, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: T3D-959
T3D Therapeutics, Inc.